Effects of FABP5-PPARγ signaling pathway on learning-memory ability and lipid metabolism in rats with vascular dementia

doi:10.12047/j.cjap.5991.2020.093

Abstract

Abstract: Objective: To investigate the effects of fatty acid binding protein 5(FABP5)- peroxisome proliferator-activated receptor gamma(PPARγ) signaling pathway on learning-memory ability and lipid metabolism in rats with vascular dementia(VD) and its mechanisms. Methods: ①VD model rats were established by ligating bilateral common carotid artery. These rats were divided into three groups: normal group (WT group), sham-operated group (sham group) and VD model group; ②WT group and FABP5 inhibitor group were set up. After four weeks, Morris water maze test was used to detect spatial learning and memory ability in rats. RT-qPCR and Western blot methods were used to detect the expressions of FABP5, PPARγ, p-PPARγ and lipoprotein lipase (LPL) in the brain at the mRNA and protein levels. The levels of TC, TG and FFA in the brain were detected by assay kits. Results: Compared with the WT group and sham group, the learning-memory ability of the VD model and the FABP5 inhibitor group were significantly decreased, and the expressions of FABP5, PPARγ, p-PPARγ and LPL were significantly decreased at mRNA level and protein level in the brain; and the levels of TC, TG and FFA were increased significantly in the brain. Conclusion: FABP5 can affect the learning-memory ability and lipid metabolism in VD rats through PPARγ and LPL.

Key words: Vascular dementia, fatty acid binding protein 5, peroxisome proliferator-activated receptor gamma, lipoprotein lipase, lipid metabolism

CLC Number:

R338.8

CHEN Dan-dan, DONG Ying, YANG Xiao-dan. Effects of FABP5-PPARγ signaling pathway on learning-memory ability and lipid metabolism in rats with vascular dementia[J]. CJAP, 2020, 36(5): 438-443.

References

[1] O'Brien JT, Thomas A. Vascular dementia[J]. Lancet, 2015, 386(10004): 1698-1706.
[2] 刘丰熙, 牛凯, 吴志刚, 等. 既济汤对脑缺血/再灌注诱导的血管性痴呆小鼠认知功能和脑内氧化应激的影响[J]. 中国应用生理学杂志, 2015, 31(2): 170-177.
[3] Barbash S, Garfinkel BP, Maoz R, et al. Alzheimer's brains show inter-related changes in RNA and lipid metabolism[J]. Neurobiol Dis, 2017, 106: 1-13.
[4] Yu S, Levi L, Casadesus G, et al. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) in the brain[J]. J Biol Chem, 2014, 289(18): 12748-12758.
[5] 刘利梅, 赵亚莉, 李丽, 等. 脂联素的信号转导通路[J]. 生理科学进展, 2005, 36(2): 130-132.
[6] Forootan FS, Forootan SS, Gou X, et al, Fatty acid activated PPARgamma promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter[J]. Oncotarget, 2016, 7(8): 9322-9339.
[7] Hayashi H. Lipid metabolism and glial lipoproteins in the central nervous system[J]. Biol Pharm Bull, 2011, 34(4): 453-461.
[8] Aditi K, Shakarad MN, Agrawal N. Altered lipid metabolism in Drosophila model of Huntington's disease[J]. Sci Rep, 2016, 6: 31411.
[9] Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the three-city study[J]. Diabetes Care, 2009, 32(1): 169-174.
[10]Iso T, Maeda K, Hanaoka H, et al. Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle[J]. Arterioscler Thromb Vasc Biol, 2013, 33(11): 2549-2557.
[11]Pan Y, Short JL, Choy KH, et al. Fatty acid-binding protein 5 at the blood-brain barrier regulates endogenous brain docosahexaenoic acid levels and cognitive function[J]. J Neurosci, 2016, 36(46): 11755-11767.
[12]Beyer AM, Baumbach GL, Halabi CM, et al. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling[J]. Hypertension, 2008, 51(4): 867-871.
[13]Zhao X, Strong R, Zhang J, et al. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia[J]. J Neurosci, 2009, 29(19): 6186-6195.
[14]Glatz T, Stock I, Nguyen-Ngoc M, et al. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain[J]. J Hypertens, 2010, 28(7): 1488-1497.
[15]Sharma B, Singh N. Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats[J]. Pharmacol Biochem Behav, 2011, 100(2): 320-329.
[16]Hanyu H, Sato T. Alzheimer's disease [J]. Nihon Rinsho, 2010, 68(2): 330-334.
[17]Prusty D, Park BH, Davis KE, et al. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes[J]. J Biol Chem, 2002, 277(48): 46226-46232.
[18]Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene[J]. EMBO J, 1996, 15(19): 5336-5348.
[19]朱铁梁, 郭一沙, 杨波, 等. 参麦注射液对高脂血症大鼠血脂的调节作用[J]. 中国应用生理学杂志, 2016, 32(3): 230-233.
[20]Nishitsuji K, Hosono T, Uchimura K, et al. Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes[J]. J Biol Chem, 2011, 286(8): 6393-6401.